ValuEngine upgraded shares of Check-Cap Ltd. (NASDAQ:CHEK) from a sell rating to a hold rating in a report released on Tuesday morning.

CHEK has been the topic of a number of other research reports. Zacks Investment Research downgraded Check-Cap from a buy rating to a hold rating in a research note on Tuesday, May 23rd. Maxim Group restated a buy rating on shares of Check-Cap in a research note on Tuesday, May 30th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Check-Cap presently has an average rating of Buy and an average price target of $5.00.

Check-Cap (NASDAQ:CHEK) traded up 1.63% during trading on Tuesday, hitting $1.87. The stock had a trading volume of 6,848 shares. Check-Cap has a 1-year low of $1.15 and a 1-year high of $3.42. The firm’s market cap is $29.23 million. The firm’s 50 day moving average is $1.89 and its 200 day moving average is $2.12.

COPYRIGHT VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/07/21/check-cap-ltd-nasdaqchek-upgraded-to-hold-by-valuengine.html.

An institutional investor recently raised its position in Check-Cap stock. Knott David M increased its stake in Check-Cap Ltd. (NASDAQ:CHEK) by 1.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,871 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Knott David M owned approximately 1.05% of Check-Cap worth $349,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 13.35% of the company’s stock.

Check-Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related stocks with our FREE daily email newsletter.